City

Tianjin (1)

Wuhan (1)

Condition

Chronic Lymphoblastic Leukemia (2)

Acute Lymphoblastic Leukemia (1)

B-cell Lymphoma (1)

Non-Hodgkin's Lymphoma (1)

Peripheral T Cell Lymphoma (1)

Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma (1)

Overall Status

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

early phase 1 (1)

phase 1 (1)

Sponsor

Institute of Hematology & Blood Diseases Hospital (1)

Wuhan Union Hospital, China (1)

Collaborator

Beijing GD Initiative Cell Therapy Technology Co., Ltd. (1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Chengdu USino Technology Biology Co., Ltd (1)

Intervention

autologous γδt cells (1)

fludarabine + cyclophosphamide + car-nk-cd19 cells (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

Other (2)

Study Type

Interventional (2)

chronic lymphoblastic leukemia

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma Trial in Wuhan (Fludarabine + Cyclophosphamide +

Recruiting

Acute Lymphoblastic Leukemia
+2 more

Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells

Wuhan, Hubei, China
+1 more

Mar 11, 2021

Non-Hodgkin's Lymphoma, Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphoblastic Leukemia Trial in Tianjin

Unknown status

Non-Hodgkin's Lymphoma
+3 more

Autologous γδT cells

Tianjin, Tianjin, China

Institute of Hematology & Blood Diseases Hospital

Sep 24, 2019